An interventional study of MiWEndo System in Colorectal Cancer, Colorectal Polyp and Colorectal Adenoma, sponsored by MiWEndo Solutions S.L.. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by MiWEndo Solutions S.L. · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 463 studies in Colorectal Neoplasms with a site in Spain — 97 open to participants now, 150 under way, 18 of them phase 3. Colorectal Neoplasms · Spain.
Among the 463 studies in Colorectal Neoplasms with a site in Spain, this one is the 329th largest by planned enrollment of the 405 interventional ones that give a count, is one of 30 that started in 2023, is one of 61 with no phase, reaches primary completion later than 43 of the 149 other live ones, and was the 364th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →97 of the 463 studies in Colorectal Neoplasms with a site in Spain are open now. Recruiting first, the newest first:
Verastem, Inc. · Sites in Spain, United States, Australia and 2 more countries
Ages 18+
Blueprint Medicines Corporation · Sites in Spain, United States
Ages 18+
Maimónides Biomedical Research Institute of Córdoba · Sites in Spain
Ages 18–75
AbbVie · Sites in Spain, United States, Belgium and 8 more countries
Ages 18+
Gilead Sciences · Sites in Spain, United States, Australia and 1 more country
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
463 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 146 · Phase 2 192 · Phase 3 73 · Phase 4 7
First in 1993; this study’s year is marked. 30 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 167 across the 405 interventional studies, 400 across the 55 observational. Of the 282 that completed or were terminated, 125 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
300 of 463 have an industry lead sponsor. The 10 most frequent:
MiWEndo Solutions S.L. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
MiWEndo Solutions S.L. has 2 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
41 of the studies in Colorectal Neoplasms with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04486378BioNTech SEA Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer | 2026-11 |
| NCT05988645MiWEndo Solutions S.L.Performance and Safety of MiWEndo-assisted Colonoscopy (MiWEndo II) | 2026-11-29 |
| NCT05789069HiFiBiO TherapeuticsA Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | 2026-12 |
| NCT06607458Delcath Systems Inc.Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease | 2026-12 |
| NCT07151040One-carbon Therapeutics ABPhase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors | 2026-12 |
Add all 41 to your calendar (.ics) → With an account.
Among the 463 studies in Colorectal Neoplasms with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study involves the planned use of a new microwave-based device during colonoscopy procedures in 50 patients to assess the performance and safety of its use for detection of colorectal polyps and lack of normal clinical practice modification. The device is a final design version, which has been previously tested in several preclinical studies (including phantom studies, an ex vivo study with human tissues, and an in vivo study with porcine model) and in a pilot study in humans (NCT05477836)
This study is designed as a single-center prospective, non-comparative study in 50 patients, whereby data will be subject to an analytical description, rather than to a statistical treatment (refer to Statistical design and analysis).
In this study the principal aims are to assess the performance and safety of the device for the detection of colorectal polyps when used as an accessory to colonoscopy. Relevant claims to verify in this study are that the device will detect in first instance polyps not detected initially with the endoscopic image and can be used without ADEs, without any change in the current clinical practice, as well as without any major difficulty by the endoscopist, neither in the preparation nor in the use of the device during exploration.
In addition, in the first phase of the study (n=15 patients), the study aims to gather real clinical data with the use of the device to optimise the processing software that will be key to demonstrate MiWEndo\'s performance on the second part of the study (n=35 patients).
Consequently, principal and secondary objectives of this investigation, are:
Principal objectives:
Secondary objectives:
The criteria were revised on the registry on Oct 8, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Patients older than 18-year-old referred for a screening or surveillance colonoscopy because of a high-risk condition of developing colorectal cancer or having colorectal polyps as fecal occult blood test (FOBT) positive, previously resected polyps under surveillance, hereditary polyposis syndromes, Lynch Syndrome or familial cancer.
These criteria will ensure the probability of finding polyps during the explorations.
All the patients will give written .
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients will be explored with MiWEndo as an accessory to colonoscopy
Device: MiWEndo System
All colonoscopies will be performed with high-definition technology. The MiWEndo System will be fitted to the tip of the endoscope before colonoscopy is started and connected to the microwave processor unit. Endoscopies will be performed by experienced endoscopists who will be previously trained on the use of the MiWEndo System. The MiWEndo Analyzer will be managed by the assistant. At the beginning of the extubation, the MiWEndo System will be turned on and the endoscopist will put music headphones on (blind to the results of MiWEndo). In case one of them identifies a polyp, the exploration will be stopped and check if it has been detected by the alternative method as well. All the polyps will be resected and sent to the Pathological Department for histological analysis following the usual clinical practice. A stopwatch will be used to measure both total procedure time and withdrawal time.
Number of polyps
With MiWEndo assisted colonoscopy, detect at least one polyp before colonoscopy in 10% of patients.
Time frame: During the procedure.
Number of adverse events.
Number of adverse events related with the use of the MiWEndo using the lexicon proposed by the American Society of Gastrointestinal Endoscopy (ASGE) (Cotton PB et al. GIE 2010;71:446-54).
Time frame: During the procedure and up to 2 weeks after.
Number of mural injuries.
Mural injuries related with the use of the MiWEndo.
Time frame: During the procedure and up to 2 weeks after.
Number and size (adenomas and polyps).
The number and size of all lesions (adenomas and all polyps) detected with MiWEndo-assisted colonoscopy.
Time frame: During procedure.
True positives (TP), False positives (FP), False negatives (FN).
The concordance with the lesions detected by the standard colonoscopy (TP, FP, FN).
Time frame: During procedure.
Patients' comfort.
Patients' feedback related to colonoscopy using the Gloucester comfort score that ranges from 1 (no discomfort) to 5 (severe discomfort).
Time frame: Immediately after the procedure and 2 weeks after.
Perception of difficulty.
Perception of difficulty by the endoscopist based on a 5-points Likert scale (very easy to very difficult or very much to very little).
Time frame: Immediately after the procedure.
Started Aug 2023 (actual). Primary completion is estimated for Nov 2026, 39 months after the start.
Of 58 industry-sponsored interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 37. This study's planned 39 months is above that.
Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Dec 2025 → Nov 2026 and completion Dec 2025 → Nov 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
MiWEndo Solutions S.L.